January 19, 2021
MHRA Grants Promising Innovative Medicine Designation to Nirsevimab
Nirsevimab is an innovative monoclonal antibody in Phase 2 and Phase 3 trials for the prevention of respiratory syncytial virus…
Pharmaceuticals, Biotechnology and Life Sciences
Nirsevimab is an innovative monoclonal antibody in Phase 2 and Phase 3 trials for the prevention of respiratory syncytial virus…
Nirsevimab is an innovative monoclonal antibody in Phase 2 and Phase 3 trials for the prevention of respiratory syncytial virus…
Nirsevimab is an innovative monoclonal antibody in Phase 2 and Phase 3 trials for the prevention of respiratory syncytial virus…
Nirsevimab is an innovative monoclonal antibody in Phase 2 and Phase 3 trials for the prevention of respiratory syncytial virus…
DUBLIN–(BUSINESS WIRE)–The “Microbial Testing Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026” report has been added…
DUBLIN–(BUSINESS WIRE)–The “Microbial Testing Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026” report has been added…
DUBLIN–(BUSINESS WIRE)–The “Microbial Testing Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026” report has been added…
DUBLIN–(BUSINESS WIRE)–The “Microbial Testing Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026” report has been added…
DUBLIN–(BUSINESS WIRE)–The “Microbial Testing Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026” report has been added…
DUBLIN–(BUSINESS WIRE)–The “Microbial Testing Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026” report has been added…